Table 1 Patient characteristics and symptomatic esophagitis
Total patients | Patients without esophagitis | Patients with esophagitis | P | ||
|---|---|---|---|---|---|
UV | MV | ||||
Gender | 0.699 | ||||
Male | 41 | 27 | 14 | ||
Female | 9 | 7 | 2 | ||
Median Age | 68 | 71 | 65 | 0.044 | >0.05 |
(95% CI) | (61–75) | (68–73) | (60–71) | ||
Clinical stage | 0.032 | >0.05 | |||
I | 14 | 12 | 2 | ||
II | 9 | 8 | 1 | ||
III | 27 | 14 | 13 | ||
Histology | 0.163 | ||||
Adenocarcinoma | 6 | 3 | 3 | ||
Squamous carcinoma | 11 | 10 | 1 | ||
NSCLC, unspecified | 33 | 21 | 12 | ||
Concurrent chemotherapy | 0.004 | 0.022 | |||
With | 33 | 18 | 15 | ||
Without | 17 | 16 | 1 | ||
Mean tumor dose | 68.0 | 66.2 | 66.2 | 0.380 | |
(95% CI, Gy) | (65.0–71.3) | (63.6–68.9) | (65.3–70.9) | ||
Maximal esophageal dose | 55.1 | 47.9 | 69.0 | 0.001 | 0.029 |
(95% CI, Gy) | (48.5–61.6) | (39.0–56.8) | (65.5–72.4) | ||
Esophagus FDG uptake change at tumour level (During-RT/pre-RT) | 1.22 | 1.11 | 1.46 | 0.002 | 0.007 |
(1.11–1.33) | (1.01–1.21) | (1.20–1.71) | |||